HAE
Haemonetics Corporation
NYSE · Healthcare · Medical - Instruments & Supplies · US
$102.92
+0.07%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.4B | 1.3B | 1.4B | 1.3B | 1.2B |
| Cost of Revenue | 576.2M | 590.4M | 582.3M | 597.1M | 545.8M |
| Gross Profit | 775.8M | 743.6M | 778.5M | 711.9M | 622.9M |
| Operating Expenses | |||||
| R&D Expense | 59.5M | 59.8M | 69.4M | 63.0M | 58.6M |
| SG&A Expense | 449.9M | 442.4M | 422.1M | 420.8M | 374.0M |
| General & Admin Expense | 118.9M | — | 414.4M | 413.7M | 366.8M |
| Selling & Marketing Expense | — | — | 7.7M | 7.1M | 7.2M |
| Other Expenses | 20.7M | — | 65.3M | 63.2M | 34.3M |
| Total Operating Expenses | 530.1M | 502.2M | 556.7M | 547.0M | 466.8M |
| Cost and Expenses | 1.1B | 1.1B | 1.1B | 1.1B | 1.0B |
| Operating Income (EBIT) | 245.7M | 241.4M | 221.8M | 164.9M | 156.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 30.6M | 28.7M | 9.7M | 13.0M | 14.6M |
| Net Interest Income | (30.6M) | (28.7M) | (9.7M) | (13.0M) | (14.6M) |
| Other Non-Op Income/Expense | (115.3M) | (113.4M) | (9.7M) | (13.0M) | (14.6M) |
| Non-Operating Income (excl Interest) | 94.6M | 84.7M | (25.3M) | (42.0M) | (11.2M) |
| EBT (Pre-Tax Income) | 130.4M | 128.0M | 212.1M | 151.9M | 141.4M |
| Income Tax Expense | 34.1M | 30.7M | 44.4M | 34.3M | 26.0M |
| Bottom Line | |||||
| Net Income | 96.3M | 97.3M | 167.7M | 117.6M | 115.4M |
| Earnings from Cont. Ops | 96.3M | 97.3M | 167.7M | 117.6M | 115.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 96.3M | 97.3M | 167.7M | 117.6M | 115.4M |
| Per Share | |||||
| Basic EPS | $2.06 | $2.05 | $3.31 | $2.32 | $2.27 |
| Diluted EPS | $2.04 | $2.05 | $3.31 | $2.29 | $2.24 |
| Revenue Per Share | $29.81 | $28.28 | $27.04 | $25.82 | $23.01 |
| Shares | |||||
| Basic Shares Outstanding | 45.4M | 47.2M | 50.3M | 50.7M | 50.8M |
| Diluted Shares Outstanding | 45.7M | 47.4M | 50.7M | 51.4M | 51.4M |
| Profitability Metrics | |||||
| EBITDA | 261.2M | 312.4M | 356.0M | 295.5M | 252.0M |
| D&A | 110.1M | 155.7M | 108.9M | 88.6M | 84.8M |
| EBIT | 151.1M | 156.7M | 247.1M | 206.8M | 167.2M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026